Core Viewpoint - Silver诺医药's new veterinary drug clinical trial application for the treatment of pet diabetes has been accepted by the Ministry of Agriculture, leading to a significant stock price increase of up to 20%, reaching HKD 31 [1] Group 1: Clinical Trial and Product Development - The core product, Isupatide α, is aimed at treating diabetes in pets, with the first phase of clinical trials expected to commence in the first quarter of this year [1] - The board believes that developing diabetes medication for pets has vast potential due to increasing consumer willingness to spend on extending their pets' lifespans [1] Group 2: Strategic Business Development - The board views this research and development as aligned with the company's long-term business strategy, establishing a solid foundation for future entry into the pet pharmaceuticals market [1]

Group 1 - The core viewpoint of the news is the successful financing of Chongqing Hanpei Biotechnology Co., Ltd., which focuses on innovative pet drugs, marking a significant achievement for the Chongqing municipal government's seed fund in supporting early-stage tech projects and facilitating technology transfer [3][4] Group 2 - Chongqing Hanpei Biotechnology was founded in September 2022 and specializes in developing first-in-class and best-in-class innovative drugs for pets, addressing clinical issues such as chronic diseases, gastrointestinal diseases, metabolic disorders, and antibiotic-resistant infections [3] - The company has multiple innovative product pipelines, with one drug for treating pet infections and gastrointestinal diseases having entered clinical trials, showcasing strong technological originality and market potential as there are no competing products with the same target globally [3] Group 3 - The Chongqing Seed Fund, established in 2024, has a total scale of 200 million yuan and is managed by the Chongqing Technology Innovation Investment Group, focusing on early-stage technology projects and startups [4] - As of October 2025, the Chongqing Seed Fund has supported over 60 projects with a total investment of 62.45 million yuan, establishing an effective early project cultivation mechanism [4] - Hanpei Biotechnology is a typical case of this systematic cultivation model, having accelerated its development and achieved recognition as a national high-tech enterprise and an innovative small and medium-sized enterprise [4]